Wojtacki J, Dziewulska-Bokiniec A, Kowalski D M, Zółtowska A, Ciesielski D, Suszko M
Division of Radiotherapy and Oncology, PCK Maritime Hospital, Gdynia, Poland.
Neoplasma. 1996;43(4):225-9.
In the present study results of serum CA 15-3 immunoassay obtained at diagnosis in 231 breast cancer women (average age: 54.6, range: 27-87 years) were correlated with prognostic factors of the disease; the cut-off level was established at 30.0 U/ ml. As a result, elevated mean values of serum CA 15-3 as well as positivity rates of the test were significantly associated with more advanced stage of breast cancer, presence of distant metastases, involvement of four and more axillary lymph nodes, high BLOOM and RICHARDSON grade [3], low contents of estrogen (ER) and progesterone (PgR) receptors. Although serum CA 15-3 concentrations should be paralleled the increasing tumor size, the difference being significant only for the proportion of positive results. Our findings suggest that pretreatment levels of CA 15-3 antigen represent the breast cancer extent and reflect the cell differentiation and aggressiveness of the tumor. We conclude that pretreatment concentrations of CA 15-3 antigen may be useful as a prognostic factor in breast cancer patients.
在本研究中，对231例乳腺癌女性患者（平均年龄：54.6岁，范围：27 - 87岁）诊断时血清CA 15 - 3免疫测定结果与疾病的预后因素进行了相关性分析；临界值设定为30.0 U/ml。结果显示，血清CA 15 - 3的平均升高值以及检测阳性率与乳腺癌更晚期、存在远处转移、四个及以上腋窝淋巴结受累、高BLOOM和RICHARDSON分级[3]、雌激素（ER）和孕激素（PgR）受体含量低显著相关。虽然血清CA 15 - 3浓度应与肿瘤大小增加平行，但差异仅在阳性结果比例方面具有显著性。我们的研究结果表明，CA 15 - 3抗原的治疗前水平代表了乳腺癌的程度，并反映了肿瘤的细胞分化和侵袭性。我们得出结论，CA 15 - 3抗原的治疗前浓度可能作为乳腺癌患者的一个预后因素。
